Quanterix Co. (NASDAQ:QTRX) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC lowered its holdings in Quanterix Co. (NASDAQ:QTRX - Free Report) by 55.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 59,100 shares of the company's stock after selling 73,005 shares during the period. Renaissance Technologies LLC owned 0.15% of Quanterix worth $628,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its holdings in Quanterix by 23.9% in the fourth quarter. JPMorgan Chase & Co. now owns 270,054 shares of the company's stock valued at $2,871,000 after acquiring an additional 52,097 shares during the last quarter. Graypoint LLC purchased a new position in shares of Quanterix in the 4th quarter worth about $691,000. Barclays PLC lifted its stake in shares of Quanterix by 42.3% in the 3rd quarter. Barclays PLC now owns 146,248 shares of the company's stock valued at $1,896,000 after purchasing an additional 43,447 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of Quanterix by 22.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 342,264 shares of the company's stock worth $3,638,000 after purchasing an additional 62,757 shares during the period. Finally, Bank of New York Mellon Corp increased its position in Quanterix by 1.8% during the 4th quarter. Bank of New York Mellon Corp now owns 108,186 shares of the company's stock worth $1,150,000 after purchasing an additional 1,963 shares in the last quarter. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Quanterix Price Performance

QTRX traded up $0.09 on Thursday, reaching $5.45. The company's stock had a trading volume of 53,229 shares, compared to its average volume of 550,268. Quanterix Co. has a 1 year low of $4.67 and a 1 year high of $19.18. The business's 50 day moving average is $6.22 and its 200 day moving average is $9.20. The stock has a market cap of $211.40 million, a price-to-earnings ratio of -5.14 and a beta of 1.12.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.03). Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. The company had revenue of $35.16 million during the quarter, compared to the consensus estimate of $34.93 million. As a group, research analysts forecast that Quanterix Co. will post -0.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Leerink Partnrs cut shares of Quanterix from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Scotiabank restated an "outperform" rating on shares of Quanterix in a report on Tuesday, March 25th. Leerink Partners reaffirmed a "market perform" rating and issued a $8.00 target price (down previously from $12.00) on shares of Quanterix in a research report on Wednesday, April 30th. Finally, Canaccord Genuity Group dropped their target price on Quanterix from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Quanterix has a consensus rating of "Moderate Buy" and an average target price of $16.20.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.